Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes

British Journal of Pharmacology

Volumn 165, Issue 4 B, 2012, Pages 1017-1033

  Barbosa, Daniel José ^a   Capela, João Paulo ^a,b   Oliveira, Jorge Ma ^a   Silva, Renata ^a   Ferreira, Luísa Maria ^c   Siopa, Filipa ^c   Branco, Paula Sério ^c   Fernandes, Eduarda ^a   Duarte, José Alberto ^a   De Lourdes Bastos, Maria ^a   Carvalho, Félix ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c DEPARTAMENTO DE QUÍMICA   (Portugal)

Author keywords

3,4 methylenedioxymethamphetamine (MDMA or 'Ecstasy'); MDMA metabolites; mitochondria; monoamine oxidase; neurotoxicity; oxidative stress; synaptosomes

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 (GLUTATHION S YL) ALPHA METHYLDOPAMINE; ACETYLCYSTEINE; ALPHA METHYLDOPAMINE; AMINE OXIDASE (FLAVIN CONTAINING); ASCORBIC ACID; DOPAMINE; DOPAMINE DERIVATIVE; GLUTATHIONE; HYDROGEN PEROXIDE; LEVODOPA; MELATONIN; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; N METHYL ALPHA METHYLDOPAMINE; NEUROTRANSMITTER; PROTEIN; QUINOPROTEIN; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN MITOCHONDRION; BRAIN SYNAPTOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DOPAMINE METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME METABOLISM; EXPERIMENTAL MODEL; GLUTATHIONE METABOLISM; LIPID PEROXIDATION; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; SEROTONIN METABOLISM; SIGNAL TRANSDUCTION; TOXICOKINETICS;

3,4-DIHYDROXYPHENYLACETIC ACID; 3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; ANTIOXIDANTS; BRAIN; DEOXYEPINEPHRINE; DOPAMINE; GLUTATHIONE; HALLUCINOGENS; HYDROGEN PEROXIDE; LEVODOPA; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; SEROTONIN; SYNAPTOSOMES;

EID: 84856316830     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01453.x     Document Type: Article

References (57)

1. Adam-Vizi V, (2005). Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal 7: 1140-1149. (Pubitemid 41232509)
2. Alves E, Summavielle T, Alves CJ, Gomes-da-Silva J, Barata JC, Fernandes E, et al,. (2007). Monoamine oxidase-B mediates ecstasy-induced neurotoxic effects to adolescent rat brain mitochondria. J Neurosci 27: 10203-10210. (Pubitemid 47450472)
3. Alves E, Summavielle T, Alves CJ, Custõdio JB, Fernandes E, Lourdes Bastos M, et al,. (2009). Ecstasy-induced oxidative stress to adolescent rat brain mitochondria in vivo: influence of monoamine oxidase type A. Addict Biol 14: 185-193.
4. Aubin N, Barneoud P, Carter C, Caille D, Sontag N, Marc C, et al,. (2004). SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4, 5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. J Pharmacol Exp Ther 310: 1171-1182. (Pubitemid 39108939)
5. Bai F, Lau SS, Monks TJ, (1999). Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chem Res Toxicol 12: 1150-1157. (Pubitemid 30013524)
6. Bai F, Jones DC, Lau SS, Monks TJ, (2001). Serotonergic neurotoxicity of 3,4-(±)-methylenedioxyamphetamine and 3,4-(±)- methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of γ-glutamyl transpeptidase. Chem Res Toxicol 14: 863-870. (Pubitemid 32661342)
7. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS, (2003). 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res 989: 205-213. (Pubitemid 37211424)
8. Cadet JL, Ladenheim B, Hirata H, Rothman RB, Ali S, Carlson E, et al,. (1995). Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse 21: 169-176.
9. Cadet JL, Thiriet N, Jayanthi S, (2001). Involvement of free radicals in MDMA-induced neurotoxicity in mice. Ann Med Interne 152: IS57-IS59.
10. Camarero J, Sanchez V, O'Shea E, Green AR, Colado MI, (2002). Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum. J Neurochem 81: 961-972. (Pubitemid 34809278)
11. Capela JP, Meisel A, Abreu AR, Branco PS, Ferreira LM, Lobo AM, et al,. (2006). Neurotoxicity of ecstasy metabolites in rat cortical neurons, and influence of hyperthermia. J Pharmacol Exp Ther 316: 53-61. (Pubitemid 41832580)
12. Capela JP, Macedo C, Branco PS, Ferreira LM, Lobo AM, Fernandes E, et al,. (2007). Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 146: 1743-1757. (Pubitemid 46795533)
13. Capela JP, Carmo H, Remião F, Bastos ML, Meisel A, Carvalho F, (2009). Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 39: 210-271.
14. Carvalho M, Hawksworth G, Milhazes N, Borges F, Monks TJ, Fernandes E, et al,. (2002). Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch Toxicol 76: 581-588.
15. Carvalho M, Milhazes N, Remiao F, Borges F, Fernandes E, Amado F, et al,. (2004a). Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch Toxicol 78: 16-24. (Pubitemid 38269935)
16. Carvalho M, Remiao F, Milhazes N, Borges F, Fernandes E, Carvalho F, et al,. (2004b). The toxicity of N-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology 200: 193-203. (Pubitemid 38798429)
17. Carvalho M, Remião F, Milhazes N, Borges F, Fernandes E, Monteiro MC, et al,. (2004c). Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem Res Toxicol 17: 623-632. (Pubitemid 38669519)
18. Carvalho M, Pontes H, Remião F, Bastos ML, Carvalho F, (2010). Mechanisms underlying the hepatotoxic effects of ecstasy. Curr Pharm Biotechnol 11: 476-495.
19. Chipana C, Camarasa J, Pubill D, Escubedo E, (2006). Protection against MDMA-induced dopaminergic neurotoxicity in mice by methyllycaconitine: involvement of nicotinic receptors. Neuropharmacology 51: 885-895. (Pubitemid 44308343)
20. Erecinska M, Nelson D, Silver IA, (1996). Metabolic and energetic properties of isolated nerve ending particles (synaptosomes). Biochim Biophys Acta 1277: 13-34. (Pubitemid 26388873)
21. Erives GV, Lau SS, Monks TJ, (2008). Accumulation of neurotoxic thioether metabolites of 3,4-(±)-methylenedioxymethamphetamine in rat brain. J Pharmacol Exp Ther 324: 284-291. (Pubitemid 350294185)
22. Esteban B, O'Shea E, Camarero J, Sanchez V, Green AR, Colado MI, (2001). 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 154: 251-260. (Pubitemid 32247186)
23. Gollamudi R, Ali SF, Lipe G, Newport G, Webb P, Lopez M, et al,. (1989). Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. Neurotoxicology 10: 455-466. (Pubitemid 20084630)
24. Granado N, O'Shea E, Bove J, Vila M, Colado MI, Moratalla R, (2008). Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J Neurochem 107: 1102-1112.
25. Hiramatsu M, Kumagai Y, Unger SE, Cho AK, (1990). Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254: 521-527. (Pubitemid 20262091)
26. Hrometz SL, Brown AW, Nichols DE, Sprague JE, (2004). 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B. Neurosci Lett 367: 56-59. (Pubitemid 39078784)
27. Huether G, Fettkötter I, Keilhoff G, Wolf G, (1997). Serotonin acts as a radical scavenger and is oxidized to a dimer during the respiratory burst of activated microglia. J Neurochem 69: 2096-2101. (Pubitemid 27452757)
28. Jones DC, Duvauchelle C, Ikegami A, Olsen CM, Lau SS, de la Torre R, et al,. (2005). Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 313: 422-431. (Pubitemid 40411369)
29. Kim S, Westphalen R, Callahan B, Hatzidimitriou G, Yuan J, Ricaurte GA, (2000). Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity. J Pharmacol Exp Ther 293: 625-633. (Pubitemid 30244116)
30. Lim HK, Foltz RL, (1988). In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem Res Toxicol 1: 370-378. (Pubitemid 19031882)
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951). Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275.
32. Macedo C, Branco PS, Ferreira LM, Lobo AM, Capela JP, Fernandes E, et al,. (2007). Sinthesis and cyclic voltammetry studies of3,4- methylenedioxymetamphetamine (MDMA) human metabolites. J Health Sci 53: 31-42. (Pubitemid 46219366)
33. Magalhães J, Ferreira R, Marques F, Olivera E, Soares J, Ascensão A, (2007). Indoor climbing elicits plasma oxidative stress. Med Sci Sports Exerc 39: 955-963. (Pubitemid 46883466)
34. Miller RT, Lau SS, Monks TJ, (1996). Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-α-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats. Chem Res Toxicol 9: 457-465.
35. Miller RT, Lau SS, Monks TJ, (1997). 2,5-bis-(glutathion-S-yl)-[alpha]- methyldopamine, a putative metabolite of (±)-3,4- methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol 323: 173-180. (Pubitemid 27152268)
36. Nagatsu T, (2004). Progress in monoamine oxidase (MAO) research in relation to genetic engineering. Neurotoxicology 25: 11-20. (Pubitemid 38044164)
37. Nicholls DG, (1993). The glutamatergic nerve terminal. Eur J Biochem 212: 613-631. (Pubitemid 23091707)
38. Ninković M, Selaković V, Dukić M, Milosavljević P, Vasiljević I, Jovanović M, et al,. (2008). Oxidative stress in rat kidneys due to 3,4-methylenedioxymetamphetamine (ecstasy) toxicity. Nephrology 13: 33-37.
39. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME, (1988). Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788-2803.
40. 2+ buffering differences of intact neurons and astrocytes from cortex and striatum. J Biol Chem 284: 5010-5020.
41. Pizarro N, Farre M, Pujadas M, Peiro AM, Roset PN, Joglar J, et al,. (2004). Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metab Dispos 32: 1001-1007. (Pubitemid 39096061)
42. Pubill D, Chipana C, Camins A, Pallàs M, Camarasa J, Escubedo E, (2005). Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol Appl Pharmacol 204: 57-68. (Pubitemid 40387567)
43. Puerta E, Hervias I, Goñi-Allo B, Zhang SF, Jordán J, Starkov AA, et al,. (2010). Methylenedioxymethamphetamine inhibits mitochondrial complex I activity in mice: a possible mechanism underlying neurotoxicity. Br J Pharmacol 160: 233-245.
44. Sanchez V, Camarero J, O'Shea E, Green AR, Colado MI, (2003). Differential effect of dietary selenium on the long-term neurotoxicity induced by MDMA in mice and rats. Neuropharmacology 44: 449-461. (Pubitemid 36293977)
45. Shenouda SK, Carvalho F, Varner KJ, (2010). The cardiovascular and cardiac actions of ecstasy and its metabolites. Curr Pharm Biotechnol 11: 470-475.
46. Shih JC, Grimsby J, Chen K, (1999). Molecular biology of monoamine oxidase A and B: their role in the degradation of serotonin. In:, Baumgarten HG, Gothert M, (eds). Serotoninergic Neurons and 5-HT Receptors in the SNC. Springer: Berlim, pp. 655-670.
47. Spencer JPE, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B, (1998). Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 71: 2112-2122. (Pubitemid 28491568)
48. Stone DM, Hanson GR, Gibb JW, (1987). Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 26: 1657-1661. (Pubitemid 18008368)
49. de la Torre R, Farré M, (2004). Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25: 505-508. (Pubitemid 39233561)
50. Tretter L, Adam-Vizi V, (2007). Uncoupling is without an effect on the production of reactive oxygen species by in situ synaptic mitochondria. J Neurochem 103: 1864-1871. (Pubitemid 350126622)
51. Tretter L, Chinopoulos C, Adam-Vizi V, (1998). Plasma Membrane Depolarization and Disturbed Na+Homeostasis induced by the Protonophore Carbonyl Cyanide-p-trifluoromethoxyphenyl-hydrazon in isolated Nerve Terminals. Mol Pharmacol 53: 734-741. (Pubitemid 28196497)
52. Uemura T, Shimazu T, Miura R, Yamano T, (1980). NADPH-dependent melanin pigment formation from 5-hydroxyindolealkylamines by hepatic and cerebral microsomes. Biochem Biophys Res Commun 93: 1074-1081.
53. Votyakova TV, Reynolds IJ, (2001). Δm-Dependent and -independent production of reactive oxygen species by rat brain mitochondria. J Neurochem 79: 266-277. (Pubitemid 32988942)
54. Whittaker VP, (1993). Thirty years of synaptosome research. J Neurocytol 22: 735-742. (Pubitemid 23294622)
55. Wrona MZ, Dryhurst G, (1988). Further insights into the oxidation chemistry of 5-hydroxytryptamine. J Pharm Sci 77: 911-917. (Pubitemid 19028887)
56. Youdim MBH, Gross A, Finberg JPM, (2001). Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132: 500-506. (Pubitemid 32142364)
57. Zhou M, Diwu Z, Panchuk-Voloshina N, Haugland RP, (1997). A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem 253: 162-168. (Pubitemid 27508167)